NCT00703378View on ClinicalTrials.gov

Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

February 29, 2012

Conditions
Solid Tumors
Interventions
DRUG

Docetaxel (Taxotere®)

Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT00703378 - Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle | Biotech Hunter | Biotech Hunter